ArticleCancer cell international2019
Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression.
Article in Cancer cell international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- The dual role of autophagy in cartilage degradation: from mechanisms to targeted therapeutics.Frontiers in cell and developmental biology · 2026Review
- Regulation of testosterone synthesis by circadian clock genes and its research progress in male diseases.Asian journal of andrology · 2025Review
- The Common Hallmarks and Interconnected Pathways of Aging, Circadian Rhythms, and Cancer: Implications for Therapeutic Strategies.Research (Washington, D.C.) · 2025Review
- Deciphering the circadian rhythm in colorectal cancer: a bibliometric analysis of research landscape and trends.Frontiers in oncology · 2025Article
- Circadian rhythm disruption and endocrine-related tumors.World journal of clinical oncology · 2024Review
- Natural Compounds for Preventing Age-Related Diseases and Cancers.International journal of molecular sciences · 2024Review
- A review for the impacts of circadian disturbance on urological cancers.Sleep and biological rhythms · 2024Review
- Identify and validate circadian regulators as potential prognostic markers and immune infiltrates in head and neck squamous cell carcinoma.Scientific reports · 2023Article
- Review
- Circadian Gene Variants in Diseases.Genes · 2023Review
- High expression of the circadian clock gene NPAS2 is associated with progression and poor prognosis of gastric cancer: A single-center study.World journal of gastroenterology · 2023Article
- Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical Overview.Clinical Medicine Insights. Oncology · 2023Review
- Circadian Rhythm Disruption as a Contributor to Racial Disparities in Prostate Cancer.Cancers · 2022Review
- Genetic Analysis Implicates Dysregulation ofInternational journal of environmental research and public health · 2022Article
- Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.Frontiers in immunology · 2022Article
- Article
- Identification of a circadian gene signature that predicts overall survival in lung adenocarcinoma.PeerJ · 2021Article
- Association between the polygenic liabilities for prostate cancer and breast cancer with biochemical recurrence after radical prostatectomy for localized prostate cancer.American journal of cancer research · 2021Article
- The Association of Sleep Disorders, Obesity and Sleep-Related Hypoxia with Cancer.Current genomics · 2020Review
- Circadian rhythm in prostate cancer: time to take notice of the clock.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo determine the association between circadian pathway genetic variants and the risk of prostate cancer progression.
methodsWe systematically evaluated 79 germline variants in nine circadian pathway genes in a cohort of 458 patients with localized prostate cancer as the discovery phase. We then replicated the significant findings in another cohort of 324 men with more advanced disease. The association of each variant with prostate cancer progression was evaluated by a log-rank test and Cox regression.
resultsA single nucleotide polymorphism of the neuronal PAS domain protein 2 (
conclusionsThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.